Edition:
United States

Organovo Holdings Inc (ONVO.OQ)

ONVO.OQ on NASDAQ Stock Exchange Global Market

1.38USD
14 Dec 2017
Change (% chg)

$-0.04 (-2.82%)
Prev Close
$1.42
Open
$1.38
Day's High
$1.42
Day's Low
$1.34
Volume
304,117
Avg. Vol
228,367
52-wk High
$4.07
52-wk Low
$1.33

Latest Key Developments (Source: Significant Developments)

Organovo posts Q3 loss per share $0.09
Thursday, 9 Nov 2017 04:05pm EST 

Nov 9 (Reuters) - Organovo Holdings Inc :Organovo announces fiscal second-quarter 2018 results; company shifts commercial focus to higher-value disease modeling opportunities and updates full-year fiscal 2018 outlook.Q2 loss per share $0.09.Q2 revenue $1.4 million versus I/B/E/S view $1.4 million.Sees FY 2018 revenue $4.5 million to $6.5 million.Q2 earnings per share view $-0.10 -- Thomson Reuters I/B/E/S.  Full Article

Organovo and Viscient Biosciences collaborate to develop custom research platform for studying liver disease
Monday, 6 Nov 2017 08:05am EST 

Nov 6 (Reuters) - Organovo Holdings Inc ::Organovo and Viscient Biosciences collaborate to develop custom research platform for studying liver disease.Says Viscient is targeting early discovery work for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis​.  Full Article

Organovo says preliminary Q2 revenue $1.3 mln - $1.4 mln
Wednesday, 4 Oct 2017 05:05pm EDT 

Oct 4 (Reuters) - Organovo Holdings Inc :Organovo announces preliminary fiscal second-quarter total revenue; company restructures to improve operational efficiency.Sees Q2 revenue $1.3 million to $1.4 million.Announced a restructuring plan to improve operational efficiency​.Organovo announced a plan to restructure its business to better focus and align resources, reducing approximately 15 positions​.Expects workforce reduction will decrease operating costs by $1.3 million in fiscal 2018 and $2.7 million in fiscal 2019​.Actions associated with restructuring are anticipated to be complete by end of calendar-year 2017​.Reduction in future operating expenses is expected to "improve" company's fiscal 2018 negative adjusted EBITDA​.  Full Article

Organovo says Keith Murphy submitted resignation as chairman of board‍​
Monday, 28 Aug 2017 09:14am EDT 

Aug 28 (Reuters) - Organovo Holdings Inc :Organovo Holdings Inc says on august 24, Keith Murphy submitted resignation as chairman of the board‍​ - sec filing.  Full Article

Organovo reports Q1 loss per share $0.10
Wednesday, 9 Aug 2017 04:05pm EDT 

Aug 10 (Reuters) - Organovo Holdings Inc -:Organovo announces fiscal first-quarter 2018 results; company affirms full-year fiscal 2018 outlook.Q1 loss per share $0.10.Sees FY 2018 revenue $6.0 million to $8.5 million.Q1 revenue $1.0 million versus I/B/E/S view $942,000.Q1 earnings per share view $-0.10 -- Thomson Reuters I/B/E/S.Says affirmed its full-year fiscal 2018 outlook.  Full Article

Organovo reports CEO transition
Tuesday, 11 Apr 2017 04:05pm EDT 

Organovo Holdings Inc : Organovo announces CEO transition . Says Taylor J. Crouch appointed CEO . Says CEO Keith Murphy resigned . Says Taylor J. Crouch named chief executive officer, effective April 24, 2017 . Says CEO Keith Murphy resigned .Organovo Holdings Inc - Murphy will remain chairman of board, will serve as an advisor to company.  Full Article

Organovo Q3 loss per share $0.09
Thursday, 9 Feb 2017 04:05pm EST 

Organovo Holdings Inc : Organovo announces fiscal third-quarter 2017 results; company updates full-year fiscal 2017 total revenue outlook . Q3 loss per share $0.09 . Sees FY 2017 revenue $3.7 million to $4.5 million . Q3 revenue $1.2 million versus I/B/E/S view $1.5 million . Q3 earnings per share view $-0.10 -- Thomson Reuters I/B/E/S .FY2017 revenue view $5.7 million -- Thomson Reuters I/B/E/S.  Full Article

Organovo announces fiscal Q2 2017 results
Thursday, 3 Nov 2016 04:05pm EDT 

Organovo Holdings Inc : Organovo announces fiscal second-quarter 2017 results; company affirms full-year fiscal 2017 and long-range outlook . Q2 loss per share $0.10 . Sees FY 2017 revenue $4.5 million to $6.2 million .Q2 revenue $1.4 million.  Full Article

Organovo Q1 loss per share $0.09
Thursday, 4 Aug 2016 04:10pm EDT 

Organovo Announces Fiscal First : Quarter 2017 results; company affirms full-year fiscal 2017 and long-range outlook . Q1 revenue $900,000 . Q1 loss per share $0.09 .Affirmed fy 2017 outlook for total revenue, net cash utilization, initiation of commercial contracting for kidney tissue product.  Full Article

BRIEF-Organovo Holdings files for common stock offering pursuant to existing Controlled Equity Offering Sales Agreement (July 20)
Thursday, 21 Jul 2016 05:09pm EDT 

Corrects headline, first bullet to add dropped words 'pursuant to existing Controlled Equity Offering Sales Agreement'; Adds additional bullet to clarify company is not offering any additional shares.Organovo Holdings Inc : Files for offering up to $26.6 million, of shares of co's common stock pursuant to an existing Controlled Equity Offering Sales Agreement - SEC filing . Originally registered up to $33 million of shares pursuant to sales agreement under registration statement expiring on July 26, 2016 .Not registering any additional shares for sale pursuant to the Sales Agreement.  Full Article

BRIEF-Organovo posts Q3 loss per share $0.09

* Organovo announces fiscal second-quarter 2018 results; company shifts commercial focus to higher-value disease modeling opportunities and updates full-year fiscal 2018 outlook